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A PILOT STUDY EVALUATING THE SAFETY AND EFFICACY OF AMD3100
FOR THE MOBILIZATION AND TRANSPLANTATION OF HLA-MATCHED
SIBLING DONOR HEMATOPOIETIC STEM CELLS IN PATIENTS WITH
ADVANCED HEMATOLOGICAL MALIGNANCIES
Devine, S.M.1, Todt, L.2, Bonde, J.2, Hess, D.2, Devine, H.1, Nolta, J.2,
Link, D.2, Calandra, G.3, Bridger, G.3, DiPersio, J.F.2 1. Ohio State
University, Columbus, OH; 2. Washington University, St. Louis, MO;
3. Anormed Inc., Langley, BC, Canada.
We are studying an antagonist of the SDF-1/CXCR4 interac-
tion, AMD3100, as a single agent to procure mobilized blood from
allogeneic donors. Eleven HLA identical siblings received one or
two doses of AMD3100 at 240 g/kg subcutaneously followed in
four hours by leukapheresis (LP). After successful collection and a
one week washout period, the same donors were remobilized using
a standard G-CSF dose and schedule. AMD3100 administration
resulted in a median 7-fold increase in peripheral CD34 cell
count from baseline within 4-6 hours compared to 21-fold after
ﬁve days of G-CSF. Nine of eleven donors mobilized following
AMD3100 collected at least 1.9  106 CD34 cells/kg recipient
weight following 1 (n  5) or 2 (n  4) LP procedures. Allografts
mobilized following AMD3100 contained less CD34 cells but
proportionately greater numbers of T-,B-, and NK-cells compared
to G-CSF allografts. AMD3100 was well tolerated and no donors
experienced any greater than grade 1 toxicity. One donor could not
tolerate apheresis and was taken off study. Eight patients have been
transplanted using the AMD3100 mobilized allografts. Two pa-
tients did not receive allografts due to progressive disease. The
median age of the recipients was 45 years (range 32-53). Three had
AML, one ALL, one CLL, one accelerated CML, and two non-
Hodgkin’s lymphoma. With a median follow-up of 290 days (range
75 to 486 days), all eight evaluable pts have engrafted neutrophils
	500/l at a median of 10 days (range 8-13) and platelets
	20000/l at a median of 19 days (range 15-25). Acute GVHD
prophylaxis employed single agent cyclosporine only. One of eight
patients to date has experienced grade 2-4 acute GVHD, and that
pt expired due to refractory GVHD. Two of ﬁve evaluable patients
have experienced extensive chronic GVHD requiring immunosup-
pressive therapy. All pts achieved early full donor chimerism of
peripheral T- and myeloid cell compartments which has been
sustained. Seven of the eight pts currently survive progression free
with full trilineage hematopoiesis. In summary, grafts mobilized
following AMD3100 differ from G-CSF mobilized allografts in the
content of CD34 and immune effector cells yet appear to recon-
stitute hematopoiesis similarly. The risk of acute GVHD does not
seem to be increased despite the transplantation of higher T-cell
doses. It appears that a chemokine antagonist given alone can safely
and rapidly induce the mobilization of a functionally competent
hematopoietic allograft.
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PHASE 2 STUDY OF TARGETED INTRAVENOUS BUSULFAN (IV BU)
COMBINED WITH FRACTIONATED TOTAL BODY IRRADIATION (FTBI)
AND ETOPOSIDE (VP-16) AS PREPARATIVE REGIMEN FOR ALLOGE-
NEIC PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) FOR
PATIENTS WITH POOR RISK LEUKEMIA
Stein, A.S.1, O’Donnell, M.R.1, Dagis, A.1, Krishnan, A.1,
Nademanee, A.1, Nakamura, R.1, Parker, P.M.1, Popplewell, L.1,
Pullarkat, V.1, Rodriguez, R.1, Rosenthal, J.1, Smith, E.P.1,
Snyder, D.S.1, Spielberger, R.2, Synold, T.1, Vora, N.1, Zain, J.1,
Sarkodee-Adoo, C.3, Forman, S.J.1 1. City of Hope Comprehensive
Cancer Center, Duarte, CA; 2. City of Hope Samaritan Transplant
Program Phoenix, Phoenix, AZ; 3. City of Hope Kaiser Permanente
Transplant Program, Duarte, CA.
Between 3/2000 and 11/2004 30 patients with high risk of relapse
post myeloablative SCT received an augmented conditioning reg-
imen consisting of IVBU followed by FTBI 1200 cGy in 10
fractions over 4 days and VP-16 30 mg/kg. BU was administered at
18 mg/m2 targeted for an AUC of 700-900 M  min every 6
hours  16 doses. Based on pharmacokinetics, doses for each
patient could be adjusted up to a maximum of 32 mg/m2 to
achieved targeted AUC. 24 patients had active leukemia (AML 9
induction failure (IF), 7 relapse, 1 untreated MDS evolved to AML,
ALL 4 IF and 3 relapse) while 6 patients had remission marrows at
time of SCT (3 AML with poor risk cytogenetics and 3 with prior
MDS evolved to AML). All patients received PBSC from HLA
matched sibling donors. GVHD prophylaxis was CSA and MMF.
With a median follow-up of 35 months (3.3, 55.3), the 2 year
probabilities of overall and event free survival were 63% (95% CI
38-82%) and 64% (95% CI 39-83%) for patients with active AML
and 50% (95% CI 17-83%) and 33% (95% CI 8-73%), respec-
tively, for ALL. The probability of relapse for AML and ALL with
active disease was 13% (95% CI 3-40%) and 58% (95% CI 19-
89%) respectively. The 2 year probability of both overall and event
free survival was 83% (95% CI 37-98%) for patients with AML in
remission at time of SCT with no relapses to date. The 100 day
non relapse mortality was 7% (95% CI 2-23%) and overall non
relapse mortality assessed at date of analysis was 30%. Grade 2-4
acute GVHD occurred in 60%; limited chronic GVHD was
present in 36% and extensive in 56% of eligible patients. This
regimen was very effective in reducing relapse in patients both with
high risk myeloid malignancy in remission and relapse at time of
SCT. It was less effective in reducing relapse in patients with ALL
transplanted with active disease.
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PENTOSTATIN IN REFRACTORY ACUTE AND CHRONIC GVHD. A SINGLE
CENTER EXPERIENCE
Arcos, M.J., Diez-Campelo, M., Caballero, M.D., Vidan, J.,
Perez-Simon, J.A., Vazquez, L., Canizo, M.C., Castilla, C.,
Mateos, J.J., Lopez, O., Perez, E., Encinas, C., Graciani, I.,
San Miguel, J.F. Hospital Clinico de Salamanca, Salamanca, Spain.
Graft-versus-host disease (GVHD) is a major complication of
allogeneic bone marrow transplantation. In refractory acute
(aGVHD) and chronic (cGVHD) GVHD, mortality is very high.
Pentostatin, a potent inhibitor of adenosine deaminase, induces
lymphocyte apoptosis and may be useful in the treatment of this
condition. Patients and Methods: We have conducted a prospec-
tive study of pentostatin in patients with refractory acute and
cGVHD. Ten patients were enrolled in the analysis, 7 with refrac-
tory aGVHD (2 skin, 5 gut and 2 liver aGVHD with a grade 2 and
3 in 2 and 5 patients, respectively) and 3 with refractory extensive
cGVHD (2 skin, 1 gut and 1 sinew as organs involved). Pentostatin
dose was 1.5-2.5 mg/m2/d by intravenous injection for 3 days
among seven patients diagnosed of refractory aGVHD (one patient
required an additional dose on day 14 and 28) and 2.5 mg/m2/
week during 4 weeks and them 4 mg/m2/2 weeks regarding 3
refractory chronic GVHD patients. Results: Regarding refractory
aGVHD, response rate was 79%, with 2 (28.5%) out of 7 patients
in complete response (CR) and 3 (43%) out of 7 patients in partial
response (PR). Two (28.5%) out of 7 aGVHD patients did not
respond. Regarding refractory cGVHD all patients included
reached responses to pentostatin, all of them PR. Only 2 out of 10
patients receiving pentostatin as refractory GVHD treatment died
due to GVHD complications. No more incidence of late infections
and other complications were observed in this subgroup of pa-
tients, the drug was well tolerated. Conclusion: Pentostatin has
activity in patients with refractory acute and chronic GVHD with-
out important side effects.
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RENAL DYSFUNCTION AFTER ALLOGENEIC STEM CELL TRANSPLANTA-
TION: RISK FACTORS AND OUTCOME
Oshima, K.1, Kanda, Y.1,2, Sato, H.2, Watanabe, T.2, Hosoya, N.1,
Chiba, S.1, Kurokawa, M.2 1. Department of Cell Therapy & Trans-
plantation Medicine, Tokyo, Japan; 2. Department of Hematology and
Oncology, Tokyo, Japan.
Background: Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) can potentially cure various malignant and non-ma-
lignant hematological disorders. However, allo-HSCT is associ-
ated with a high risk of treatment-related mortality. Renal dys-
function is one of frequent, life-threatening treatment-related
toxicities. In this study, we evaluated the incidence and risk factors
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